Medindia

X

Early Line Dominance of Teva's Copaxone and Biogen Idec's Avonex in the Treatment of Multiple Sclerosis To Diminish Following the Launch of Oral Disease-Modifying Therapies

Monday, April 19, 2010 General News J E 4
Advertisement
However, Half of Surveyed Neurologists Do Not Expect to Change Their Prescribing Habits of Copaxone or IFN-beta Therapies by 2012, According to a New Report from Decision Resources

Decision Resources

Decision Resources, Inc.

Lisa Osgood

Chris Comfort

781-296-2606

781-296-2597

losgood@hl-isy.com

ccomfort@dresources.com

Advertisement


Advertisement

You May Also Like

Advertisement
View All

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
s
Qforma Appoints New Director, Client Services
S
Epix Pharmaceuticals, Inc. Announces the May 28, 2...